AIHTA - Publications - Search - Datopotamab deruxtecan (Datroway®) for the treatment of unresectable or metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer

Marschik, T. and Rothschedl, E. and Geiger-Gritsch, S. (2025): Datopotamab deruxtecan (Datroway®) for the treatment of unresectable or metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer. Fact Sheet Nr. 210.

[thumbnail of Fact Sheet Nr.210.pdf]
Preview
 PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
676kB

Item Type:Horizon Scanning of Medicines
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WP Gynaecology > WP 800-910 Breast
Language:English
Series Name:Fact Sheet Nr. 210
Deposited on:10 Nov 2025 11:38
Last Modified:10 Nov 2025 11:38

Repository Staff Only: item control page